TransMedics Group Competitors

TransMedics Group (NASDAQ:TMDX) and InMode (NASDAQ:INMD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Institutional and Insider Ownership

76.7% of TransMedics Group shares are held by institutional investors. Comparatively, 35.7% of InMode shares are held by institutional investors. 13.1% of TransMedics Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

TransMedics Group has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for TransMedics Group and InMode, as provided by MarketBeat.com.

TransMedics Group presently has a consensus price target of $44.20, suggesting a potential upside of 52.73%. InMode has a consensus price target of $71.50, suggesting a potential downside of 14.17%. Given TransMedics Group's higher possible upside, analysts clearly believe TransMedics Group is more favorable than InMode.

Profitability

This table compares TransMedics Group and InMode's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares TransMedics Group and InMode's gross revenue, earnings per share and valuation.

InMode has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Summary

InMode beats TransMedics Group on 9 of the 14 factors compared between the two stocks.

TransMedics Group (NASDAQ:TMDX) and Outset Medical (NASDAQ:OM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Profitability

This table compares TransMedics Group and Outset Medical's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares TransMedics Group and Outset Medical's gross revenue, earnings per share and valuation.

Outset Medical has lower revenue, but higher earnings than TransMedics Group.

Institutional and Insider Ownership

76.7% of TransMedics Group shares are held by institutional investors. Comparatively, 84.6% of Outset Medical shares are held by institutional investors. 13.1% of TransMedics Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and target prices for TransMedics Group and Outset Medical, as provided by MarketBeat.com.

TransMedics Group presently has a consensus price target of $44.20, suggesting a potential upside of 52.73%. Outset Medical has a consensus price target of $56.50, suggesting a potential upside of 3.76%. Given TransMedics Group's stronger consensus rating and higher possible upside, analysts clearly believe TransMedics Group is more favorable than Outset Medical.

Summary

Outset Medical beats TransMedics Group on 5 of the 9 factors compared between the two stocks.

TransMedics Group (NASDAQ:TMDX) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for TransMedics Group and BioLife Solutions, as provided by MarketBeat.

TransMedics Group currently has a consensus target price of $44.20, indicating a potential upside of 52.73%. BioLife Solutions has a consensus target price of $46.6667, indicating a potential upside of 38.03%. Given TransMedics Group's higher probable upside, research analysts plainly believe TransMedics Group is more favorable than BioLife Solutions.

Institutional & Insider Ownership

76.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 67.7% of BioLife Solutions shares are owned by institutional investors. 13.1% of TransMedics Group shares are owned by insiders. Comparatively, 22.3% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

TransMedics Group has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.

Profitability

This table compares TransMedics Group and BioLife Solutions' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares TransMedics Group and BioLife Solutions' revenue, earnings per share and valuation.

BioLife Solutions has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Summary

BioLife Solutions beats TransMedics Group on 10 of the 14 factors compared between the two stocks.

Natus Medical (NASDAQ:NTUS) and TransMedics Group (NASDAQ:TMDX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability and earnings.

Earnings and Valuation

This table compares Natus Medical and TransMedics Group's revenue, earnings per share (EPS) and valuation.

Natus Medical has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than Natus Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Natus Medical and TransMedics Group, as provided by MarketBeat.

TransMedics Group has a consensus price target of $44.20, indicating a potential upside of 52.73%. Given TransMedics Group's stronger consensus rating and higher probable upside, analysts clearly believe TransMedics Group is more favorable than Natus Medical.

Volatility and Risk

Natus Medical has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500.

Profitability

This table compares Natus Medical and TransMedics Group's net margins, return on equity and return on assets.

Institutional & Insider Ownership

89.7% of Natus Medical shares are owned by institutional investors. Comparatively, 76.7% of TransMedics Group shares are owned by institutional investors. 1.5% of Natus Medical shares are owned by company insiders. Comparatively, 13.1% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

TransMedics Group (NASDAQ:TMDX) and AxoGen (NASDAQ:AXGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Analyst Ratings

This is a breakdown of current recommendations for TransMedics Group and AxoGen, as reported by MarketBeat.com.

TransMedics Group presently has a consensus target price of $44.20, indicating a potential upside of 52.73%. AxoGen has a consensus target price of $23.75, indicating a potential upside of 21.48%. Given TransMedics Group's higher probable upside, analysts plainly believe TransMedics Group is more favorable than AxoGen.

Institutional & Insider Ownership

76.7% of TransMedics Group shares are held by institutional investors. Comparatively, 78.4% of AxoGen shares are held by institutional investors. 13.1% of TransMedics Group shares are held by insiders. Comparatively, 6.9% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares TransMedics Group and AxoGen's top-line revenue, earnings per share and valuation.

AxoGen has higher revenue and earnings than TransMedics Group. AxoGen is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

TransMedics Group has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, AxoGen has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500.

Profitability

This table compares TransMedics Group and AxoGen's net margins, return on equity and return on assets.

Summary

AxoGen beats TransMedics Group on 7 of the 12 factors compared between the two stocks.

TransMedics Group (NASDAQ:TMDX) and ViewRay (NASDAQ:VRAY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Insider & Institutional Ownership

76.7% of TransMedics Group shares are held by institutional investors. Comparatively, 83.0% of ViewRay shares are held by institutional investors. 13.1% of TransMedics Group shares are held by insiders. Comparatively, 15.5% of ViewRay shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for TransMedics Group and ViewRay, as provided by MarketBeat.com.

TransMedics Group presently has a consensus price target of $44.20, suggesting a potential upside of 52.73%. ViewRay has a consensus price target of $4.50, suggesting a potential upside of 2.97%. Given TransMedics Group's stronger consensus rating and higher probable upside, research analysts clearly believe TransMedics Group is more favorable than ViewRay.

Earnings & Valuation

This table compares TransMedics Group and ViewRay's top-line revenue, earnings per share and valuation.

TransMedics Group has higher earnings, but lower revenue than ViewRay. TransMedics Group is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

TransMedics Group has a beta of 2.16, meaning that its share price is 116% more volatile than the S&P 500. Comparatively, ViewRay has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.

Profitability

This table compares TransMedics Group and ViewRay's net margins, return on equity and return on assets.

Summary

TransMedics Group beats ViewRay on 8 of the 14 factors compared between the two stocks.